MGMT promoter methylation predicts overall survival after chemotherapy for 1p/19q-codeleted gliomas.
Connor J KinslowAli I RaeKekoa TaparraPrashanth KumarMarkus D SiegelinJack GrinbandBrian J A GillGuy M McKhannMichael B SistiJeffrey N BrucePeter D CanollFabio M IwamotoDavid P HorowitzLisa A KachnicAlfred I NeugutJames B YuSimon K ChengTony J C WangPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Our study demonstrates an association between mMGMT and OS in 1p/19qcodeleted gliomas. MGMT promoter status should be considered as a stratification factor in future clinical trials of 1p/19q-codeleted gliomas that use OS as an endpoint.